Capricor Therapeutics Inc.

2 months ago · businesswire.com

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR) resulting from allegations that Capricor may have issued materially misleading business information to the investing public. So What: If you purchased Capricor securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ar.

2 months ago · businesswire.com

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON CAPRICOR THERAPEUTICS, INC. (CAPR), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On July 27, 2026, the US Food and Drug Administr.

2 months ago · globenewswire.com

SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) or certain of its officers and directors violated federal securities laws by misrepresenting or failing to timely disclose material information to investors.

2 months ago · globenewswire.com

ATLANTA, July 27, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) complied with federal securities laws. On July 27, 2026, STAT News reported that: “The Food and Drug Administration said Monday that Capricor Therapeutics' stem cell treatment for Duchenne muscular dystrophy did not meet the objectives of a Phase 3 trial — contrary to the company's claims last year.” Following this news, the price of the Company's stock dropped.

2 months ago · benzinga.com

Capricor Therapeutics Inc. (NASDAQ:CAPR) stock is trading lower on Monday.

2 months ago · benzinga.com

‘Pharma Bro' Martin Shkreli is publicly accusing Capricor Therapeutics (NASDAQ:CAPR) of fraud and alleging legal action will be taken against its CEO and a consultant over patient data.

2 months ago · globenewswire.com

SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today provided an update ahead of the Company's upcoming FDA Advisory Committee meeting, at which an independent advisory committee will discuss Capricor's Biologics License Application (BLA) for Deramiocel, an investigational cell therapy for the treatment of Duchenne muscular dystrophy (DMD), as part of the FDA's ongoing review of the application.

2 months ago · proactiveinvestors.com

Capricor Therapeutics (NASDAQ:CAPR) shares fell about 67% on Monday after US Food and Drug Administration (FDA) staff reviewers raised concerns about the evidence supporting the effectiveness of the company's experimental cell therapy, deramiocel, for Duchenne muscular dystrophy (DMD)-associated cardiomyopathy. The FDA released briefing documents ahead of a July 29 meeting of its Cellular, Tissue, and Gene Therapies Advisory Committee, which will review the therapy's efficacy and overall risk-benefit profile before the agency's August 22 Prescription Drug User Fee Act (PDUFA) target action date.

2 months ago · benzinga.com

Shares of Capricor Therapeutics Inc. (NASDAQ:CAPR) dropped more than 60% Monday after the FDA posted briefing documents ahead of the company's July 29 advisory committee meeting.

2 months ago · reuters.com

U.S. Food ​and Drug Administration ‌staff reviewers raised ​concerns ​about whether Capricor ⁠Therapeutics' ​cell therapy ​deramiocel has sufficient evidence of ​effectiveness ​for treating cardiomyopathy ‌in ⁠Duchenne muscular dystrophy, according to ​briefing ​documents ⁠released on ​Monday.